U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitisElanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolioIn a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of dogs to clinical remission of itch, compared to 53% of dogs treated with Apoquel® (oclacitinib tablet)1*Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming days

Navident EVO will apply its dynamic navigation technology to provide minimally invasive access to tooth structures requiring endodontic treatment. The dual advantage of preserving tooth structure and making the procedure more efficient significantly benefits the dentist and the patient. The advantages are clear: Less invasive access of calcified and hidden canalsPreserved tooth structureSaved time in locating and accessing canals.

Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, today announces that the research results of the preclinical studies for PD-L1-targeted photoimmunotherapy were presented at the 83rd Annual Meeting of the Japanese Cancer Association (JCA2024) in Fukuoka, Japan on September 20, 2024 (JST). The key findings presented at JCA2024 Abstract Title: PD-L1 photoimmunotherapy kills immunosuppressive myeloid cells to activate local and systemic antitumor immunity Presenter: Amy H. Thorne, Ph.D. (Rakuten Medical, Inc.) Abstract Number: 30050 It has been observed in in vitro studies that this photoimmunotherapy has a dual mechanism of action (MoA): depletion of PD-L1 expressing tumor cells and depletion of PD-L1 expressing immunosuppressive cells such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). In addition to this dual MoA, the potential for systemic immune checkpoint inhibition was… 

Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approachesSIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival secondary endpoint with high statistical significanceIomab-B was well tolerated in the older, heavily pretreated relapsed/refractory AML patients with active disease enrolled in the SIERRA trialActinium to seek strategic partner for Iomab-B for further development in the U.S. following completion of interactions with FDA for additional head-to-head clinical trial to demonstrate overall survival benefit

Kangpu Biopharmaceuticals, a clinical-stage company based in Hefei, China, announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects in China. The randomized, double-blind, placebo-controlled, and food effects (FE) study aimed to assess the safety and tolerability of multiple oral doses of KPG-818 in male and female healthy participants over a treatment period of 14 days and a follow-up period of 4 weeks, to characterize the single and multiple oral dose pharmacokinetics (PK) of KPG-818, and to select dosing regimens of KPG-818 for future clinical trials. A total of 30 participants were randomized to three escalating cohorts (n=10 each; 8 KPG-818, 2 placebo) receiving 0.15 mg, 0.6 mg, 2 mg or placebo once daily. In the FE cohort, 12 participants received single dose of 0.6 mg KPG-818 with and without food. KPG-818 is… 

The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe, showcasing the latest advancements in the field and providing high-quality educational and networking opportunities for oncology professionals. Biosyngen, an innovative biotechnology company specializing in immune cell therapies, has showcased its groundbreaking technology on gene-modified, functionally enhanced tumor-infiltrating lymphocytes (TILs) derived from liver cancer biopsy samples. BioSyngen has secured ten clinical trial approvals in China and the U.S. for its innovative fourth-generation oncology therapies. Currently, our leading pipeline product, BRG01, is in the pivotal Phase II clinical trial stage for solid tumors. Additionally, the first patients have been enrolled in the Phase I trials for… 

Einem neuen Bericht zufolge hat die Wissenschaft mehr als genügend Beweise geliefert, um einen kollektiven und globalen Ansatz zur Eindämmung der weiteren Ausbreitung der Plastikverschmutzung zu entwickeln. Eine internationale Expertengruppe schreibt in der Fachzeitschrift Science , dass der Bedarf an weltweiten Maßnahmen zur Bekämpfung aller Formen von Plastik- und Mikroplastikmüll noch nie so dringend gewesen sei. Es sei klar, dass die bestehende nationale Gesetzgebung allein nicht ausreiche, um die Herausforderung zu bewältigen, sagen sie, und der Plastikverschmutzungsvertrag der Vereinten Nationen – der im November 2024 seine fünfte Beratungsrunde durchläuft – biete eine „greifbare Chance“ für gemeinsames internationales Handeln. Damit ein solcher Vertrag jedoch wirklich wirksam ist, muss er sich zu einer allgemeinen Reduzierung der Kunststoffproduktion verpflichten und gleichzeitig Maßnahmen zur Verringerung der Emission und Freisetzung von Mikroplastikpartikeln über den gesamten Kunststofflebenszyklus hinweg ergreifen. Andernfalls, so fügen die Forscher hinzu, bestehe… 

Cambrex, ein weltweit führendes Auftragsentwicklungs- und -herstellungsunternehmen (Contract Development and Manufacturing Organization, CDMO), gab heute bekannt, dass Snapdragon Chemistry, ein Unternehmen von Cambrex, erfolgreich eine neue Flüssigphasen-Peptidsynthesetechnologie (Liquid-Phase Peptide Synthesis, LPPS) entwickelt hat, die herkömmliche Chargenreaktoren für pharmazeutische Wirkstoffe und einen kontinuierlichen Durchfluss nutzt, wodurch die Abhängigkeit von speziellen Festphasenreaktoren entfällt. Die neue LPPS-Technologie reduziert den Lösungsmittelbedarf und den Bedarf an überschüssigen Reagenzien im Vergleich zu herkömmlichen Peptidsyntheseverfahren in fester Form erheblich. Die LPPS-Technologie unterstützt Peptide mit einer Länge von bis zu 12 Aminosäure-Resten, während größere Peptide anschließend in der Flüssigphase mit Hilfe eines konvergenten Fragmentkopplungsansatzes zusammengesetzt werden. Die mit der LPPS-Technologie von Cambrex entwickelten Verfahren lassen sich genauso skalieren wie herkömmliche kleine Moleküle. Zusätzlich zur LPPS hat Cambrex auch einzigartige Fähigkeiten im Bereich der Peptid- und Proteinkristallisation entwickelt, einschließlich einer Kristallisations-Screening-Plattform speziell für die Entdeckung kristalliner Formen von Peptiden… 

Human breast milk regulates a baby’s mix of microbes, or microbiome, during the infant’s first year of life. This in turn lowers the child’s risk of developing asthma, a new study shows. Led by researchers at NYU Langone Health and the University of Manitoba, the study results showed that breastfeeding beyond three months supports the gradual maturation of the microbiome in the infant’s digestive system and nasal cavity, the upper part of the respiratory tract. Conversely, stopping breastfeeding earlier than three months disrupts the paced development of the microbiome and was linked to a higher risk of preschool asthma. Some components in breast milk, such as complex sugars called human milk oligosaccharides, can only be broken down with the help of certain microbes. This provides a competitive advantage to microbes capable of digesting these sugars. By contrast, infants who are…